Troponin acts as atherosclerotic
biomarker in patients with lupus
By Sara Freeman
VIDEO HIGHLIGHTS: Click here to watch a video interview with Prof. Karim Sacré of Bichat Hospital,
University of Paris-Diderot, France.
Measuring levels of troponin, a
well-known cardiac biomarker,
could help identify patients with
systemic lupus erythematosus
(SLE) at particularly high risk for
cardiovascular (CV) events, according to the results of a cross-sectional study presented at the
Prof. Karim Sacré presented the
findings of the study that looked
for possible biomarkers of atherosclerosis in patients with SLE and
provided preliminary evidence that
high-sensitivity troponin T (
HS-c Tn T) was predictive regardless
of whether or not patients already
had visible atherosclerotic plaques
on vascular ultrasound.
“Patients with SLE have been
known to be at risk for cardiovas-
cular disease for at least a decade,”
Prof. Sacré of Bichat Hospital, Uni-
versity of Paris-Diderot, France,
said in an interview at the meeting.
Today, SLE is considered an inde-
pendent risk factor for CV events,
much like diabetes, he added.
However, determining which
patients with lupus will and which
will not develop cardiac problems
is still tricky in routine practice. This
is because the traditional ways of
assessing CV events do not fully account for the increased risk seen in
lupus patients. Indeed, the Framingham risk score, which is based on
several risk factors, such as tobacco
use, hypertension, and dyslipidae-mia, has been shown to underestimate the cardiovascular risk of
lupus patients, he observed.
“So, we need something that will
help clinicians to better define the
real risk of cardiovascular disease
in such populations,” he said at an
earlier press conference.
Thus, the objective of the study
he presented was to try to find a
biomarker in the blood that might
aid clinicians in identifying which
patients who had SLE and no obvi-
ous cardiac symptoms might be at
risk for future CV events.
The study involved 63 patients
with SLE who were consecutively recruited and 18 individuals
without SLE who were used as
controls. None had any symptoms
of cardiovascular disease at recruitment, and all were assessed prospectively by vascular ultrasound
for the presence of atherosclerotic
plaques in the carotid artery.
The concentration of HS-c TnT
was measured in the serum by using an electrochemiluminescence
method, which could detect a concentration level greater than 3 ng/L.
At recruitment, the Framingham
risk score was low ( 2. 1) in both
continued on following page